Prospects in radionuclide imaging of prostate cancer

Prostate

Volumn 72, Issue 11, 2012, Pages 1262-1272

  Lütje, Susanne ^a   Boerman, Otto C ^a   Van Rij, Catharina M ^a   Sedelaar, Michiel ^a   Helfrich, Wijnand ^b   Oyen, Wim J G ^a   Mulders, Peter F A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

PET CT; prostate cancer; radionuclide imaging; SPECT

Indexed keywords

3' FLUOROTHYMIDINE F 18; BOMBESIN; CAPROMAB PENDETIDE IN 111; CHOLINE KINASE; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; GASTRIN RELEASING PEPTIDE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; BINDING AFFINITY; BONE METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; GLYCOLYSIS; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR GROWTH; TUMOR LOCALIZATION; UPREGULATION; URINARY EXCRETION;

HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 84862862905     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22462     Document Type: Review

References (66)

1. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46 (4): 765-781.
2. Kularatne SA, Wang K, Santhapuram HKR, Low PS,. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm 2009; 6 (3): 780-789.
3. Turkbey B, Albert PS, Kurdziel K, Choyke PL,. Imaging localized prostate cancer: Current approaches and new developments. Am J Roentgenol 2009; 192 (6): 1471-1480.
4. Choi M, Hung AY,. Technological advances in radiation therapy for prostate cancer. Curr Urol Rep 2010; 11 (3): 172-179.
5. Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ,. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol 2011; 12 (2): 181-191.
6. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT,. Imaging prostate cancer: A multidisciplinary perspective. Radiology 2007; 243 (1): 28-53.
7. Cornud F, Hamida K, Flam T, Hélénon O, Chrétien Y, Thiounn N, Correas JM, Casanova JM, Moreau JF,. Endorectal color Doppler sonography and endorectal MR imaging features of nonpalpable prostate cancer: Correlation with radical prostatectomy findings. Am J Roentgenol 2000; 175 (4): 1161-1168.
8. Turkbey B, Pinto PA, Choyke PL,. Imaging techniques for prostate cancer: Implications for focal therapy. Nat Rev Urol 2009; 6 (4): 191-203.
9. Kwee TC, Takahara T, Ochiai R, Nievelstein RAJ, Luijten PR,. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): Features and potential applications in oncology. Eur J Radiol 2008; 18 (9): 1937-1952.
10. Costello LC, Franklin RB, Feng P,. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 2005; 5 (3): 143-153.
11. Ramírez de Molina A, Rodríguez-González A, Gutiérrez R, Martínez-Piñeiro L, Sánchez J, Bonilla F, Rosell R, Lacal J,. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002; 296 (3): 580-583.
12. Shukla-Dave A, Hricak H, Moskowitz C, Ishill N, Akin O, Kuroiwa K, Spector J, Kumar M, Reuter VE, Koutcher JA, Zakian KL,. Detection of prostate cancer with MR spectroscopic imaging: An expanded paradigm incorporating polyamines. Radiology 2007; 245 (2): 499-506.
13. Casciani E, Polettini E, Bertini L, Masselli G, Emiliozzi P, Amini M, Pansadoro V, Gualdi GF,. Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone. Abdom Imaging 2007; 32 (6): 796-802.
14. Ocak I, Bernardo M, Metzger G, Barrett T, Pinto P, Albert PS, Choyke PL,. Dynamic contrast-enhanced MRI of prostate cancer at 3T: A study of pharmacokinetic parameters. Am J Roentgenol 2007; 189 (4): 849.
15. Heesakkers RA, Hövels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP, Severens JL, Adang EM, van der Kaa CH, Fütterer JJ, Barentsz J,. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: A prospective multicohort study. Lancet Oncol 2008; 9 (9): 850-856.
16. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R,. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 349 (10): 1010.
17. Martin AL, Hickey JL, Ablack A, Lewis JD, Leonard GL, Gillies ER,. Synthesis of bombesin-functionalized iron oxide nanoparticles and their specific uptake in prostate cancer cells. J Nanoparticle Res 2010; 12 (5): 1599-1608.
18. Van der Heiden MG, Cantley LC, Thompson CB,. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009; 324 (5930): 1029-1033.
19. Jana S, Blaufox MD,. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 2006; 36 (1): 51-72.
20. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK,. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001; 57 (1): 108-111.
21. 18F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumour models. Eur J Nucl Med Mol Imaging 2011; 38 (1): 81-89.
22. Bouchelouche K, Tagawa ST, Goldsmith SJ, Turkbey B, Capala J, Choyke P,. PET/CT imaging and radioimmunotherapy of prostate cancer. Semin Nucl Med 2011; 41 (1): 29-44.
23. Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, de Jong IJ,. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005; 32 (6): 668-673.
24. Zheng QH, Gardener TA, Raikwar S, Kao C, Stone KL, Martinez TD, Mock BH, Fei X, Wang JQ, Hutchins GD,. [11C]choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorg Med Chem 2004; 12 (11): 2887-2893.
25. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ,. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002; 42 (1): 18-23.
26. Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, Möller P, Wiegel T, Kuefer R, Gschwend JE,. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. Br J Urol Int 2007; 100 (4): 786-793.
27. Eschmann SM, Pfannenberg AC, Rieger A, Aschoff P, Müller M, Paulsen F, Anastasiadis A, Claussen CD, Bares R, Schlemmer HP,. Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin 2007; 46 (5): 161-168.
28. Apolo AB, Pandit-Taskar N, Morris MJ,. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med 2008; 49 (12): 2031-2041.
29. Albrecht S, Buchegger F, Soloviev D, Zaidi H, Vees H, Khan HG, Keller A, Bischof F, Delaloye A, Ratib O, Miralbell R,. (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 2007; 34 (2): 185-196.
30. Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, Kibel AS, Andriole GL, Picus J, Welch MJ,. 11C-acetate PET imaging of prostate cancer: Detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44 (4): 549-555.
31. Ponde DE, Dence CS, Oyama N, Kim J, Tai YC, Laforest R, Siegel BA, Welch MJ,. 18F-fluoroactetate: A potential acetate analog for prostate tumor imaging-In vivo evaluation of 18F-fluoroactetate versus 11C-acetate. J Nucl Med 2007; 48 (3): 420-428.
32. Matthies A, Ezziddin S, Ulrich EM, Palmedo H, Biersack HJ, Bender H, Guhlke S,. Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT. Eur J Nucl Med Mol Imaging 2004; 31 (5): 797.
33. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I,. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006; 47 (2): 287-297.
34. Fogelman I, Cook G, Israel O, Van der Wall H,. Positron emission tomography and bone metastases. Semin Nucl Med 2005; 35 (2): 135-142.
35. Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, Lievshitz G, Ron I, Mishani E,. Assessment of malignant skeletal disease: Initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2004; 45 (2): 272-278.
36. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, Broinger G, Stoiber F, Foglman I, Langsteger W,. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: A comparative study. Eur J Nucl Med Mol Imaging 2008; 35 (10): 1766-1774.
37. Pillarsetty N, Punzalan B, Larson SM,. 2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer. J Nucl Med 2009; 50 (10): 1709-1714.
38. Dehdashti F, Picus J, Michalski JM, Dence CS, Siegel BA, Katzenellenbogen JA, Welch MJ,. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005; 32 (3): 344-350.
39. Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J, Sharp TL, Welch MJ,. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem 2003; 14 (4): 756-763.
40. Schroeder RP, Müller C, Reneman S, Melis ML, Breeman WA, de Blois E, Bangma CH, Krenning EP, van Weerden WM, de Jong M,. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging 2010; 37 (7): 1386-1396.
41. 2], in a prostate tumor xenografted mouse model. Nucl Med Biol 2010; 37 (7): 751-761.
42. Scopinaro F, De Vincentis G, Varvarigou AD, Laurenti C, Iori F, Remediani S, Chiarini S, Stella S,. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging 2003; 30 (10): 1378-1382.
43. De Vincentis G, Remediani S, Varvarigou AD, Di Santo G, Iori F, Laurenti C, Scopinaro F,. Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancer. Cancer Biother Radiopharm 2004; 19 (1): 81-84.
44. Cooper CR, Chay CH, Pienta KJ,. The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 2002; 4 (3): 191-194.
45. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M,. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005; 2 (3): e70.
46. Li ZB, Wu Z, Chen K, Ryu EK, Chen X,. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med 2008; 49 (3): 453-461.
47. Liu Z, Li ZB, Cao Q, Liu S, Wang F, Chen X,. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med 2009; 50 (7): 1168-1177.
48. Bander NH,. Technology insight: Monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006; 3 (4): 216-225.
49. Schettino CJ, Kramer EL, Noz ME, Taneja S, Padmanabhan P, Lepor H,. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. Am J Roentgenol 2004; 183 (2): 519-524.
50. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH,. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998; 58 (18): 4055-4060.
51. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH,. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003; 44 (4): 610-617.
52. Alt K, Wiehr S, Ehrlichmann W, Reischl G, Wolf P, Pichler BJ, Elsässer-Beile U, Bühler P,. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA. Prostate 2010; 70 (13): 1413-1421.
53. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ,. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170 (5): 1717-1721.
54. Tagawa ST, Milowsky MI, Morris MJ, Vallabhajosula S, Goldsmith S, Matulich D, Kaplan J, Berger F, Scher HI, Bander NH, Nanus DM,. Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients with metastatic castrate-resistent prostate cancer. J Clin Oncol 2008; 26 (15S): 5140.
55. Wolf P, Freudenberg N, Bühler P, Alt K, Schultze-Seemann W, Wetterauer U, Elsässer-Beile U,. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate 2010; 70 (5): 562-569.
56. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE,. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000; 19 (10): 1288-1296.
57. van Rij C, Franssen G, Sharkey R, Frielink C, McBride B, Oyen W, Goldenberg D, Boerman O,. Pretargeted immunoPET imaging and radioimmunotherapy (RIT) of prostate cancer with an anti-EGP1 x anti-HSG bispecific antibody (bsMAb). J Nucl Med 2010; 51 (Supplement 2): 501.
58. Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE,. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 2005; 11 (7): 2591-2596.
59. Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE,. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 2007; 30 (4): 396-405.
60. Leyton JV, Olafsen T, Lepin EJ, Hahm S, Bauer KB, Reiter RE, Wu AM,. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res 2008; 14 (22): 7488-7496.
61. He J, Wang Y, Feng J, Zhu X, Lan X, Iyer AK, Zhang N, Seo Y, VanBrocklin HF, Liu B,. Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment. J Nucl Med 2010; 51 (3): 427-432.
62. Nuñez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM,. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 2002; 43 (1): 46-55.
63. Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, Bowman FD, Issa MM, Goodman MM,. Initial experience with the radiotracer anti-1-amino-3-18F- fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007; 48 (1): 56-63.
64. Hong H, Zhang Y, Sun J, Cai W,. Positron emission tomography imaging of prostate cancer. Amino Acids 2010; 39 (1): 11-27.
65. Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP, Pomper MG,. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer. Clin Cancer Res 2005; 11 (11): 4022-4028.
66. Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, Prideaux A, Fox JJ, Sgouros G, Kozikowski AP, Pomper MG,. N-[N-[(S)-1, 3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl- L- cysteine, [18F]DCFBC: A new imaging probe for prostate cancer. Clin Cancer Res 2008; 14 (10): 3036-3043.